Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Total Liabilities
Everything the company owes to creditors and other parties.
Immunome, Inc.NASDAQ: IMNM
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 44.5% from a year ago
Total liabilities stood at $51.22M at the end of Q3 FY2026, up 44.5% from a year earlier and up 27.1% from the prior quarter. Over 3 fiscal years it compounded at +87.6% a year.
Context
- Total liabilities amounted to 10.1% of total assets at the end of Q3 FY2026, down 1.7 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +44.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 48.85M USD
- Year-over-year change
- -17.3%
- 4-year CAGR
- +49.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.85M | -17.3% |
| FY2024 | 2024-12-31 | 59.08M | +106.1% |
| FY2023 | 2023-12-31 | 28.66M | +287.6% |
| FY2022 | 2022-12-31 | 7.39M | -24.1% |
| FY2021 | 2021-12-31 | 9.74M | — |
Total Liabilities vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +44.5% is the 3rd highest of 11, against a peer median of +17.5%.
- Total liabilities amounts to 10.1% of total assets for IMNM, versus a peer median of 13.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $678.42M USD | +4.4% | +54.0% | 63.3% | |
| Mar 2026 | $308.88M USD | -11.0% | +17.3% | 127.6% | |
| Mar 2026 | $196.68M USD | +35.2% | +10.9% | 90.3% | |
| Mar 2026 | $98.08M USD | -31.7% | -8.4% | 15.0% | |
| Mar 2026 | €87.55M EUR | -16.7% | -26.2% | 16.1% | |
| Sep 2026 | $72.06M USD | +43.9% | +28.1% | 10.0% | |
| Sep 2026 | $51.22M USD | +44.5% | +87.6% | 10.1% | |
| Mar 2026 | $25.32M USD | +95.4% | +45.8% | 7.2% | |
| Mar 2026 | $12.52M USD | +23.8% | -6.5% | 4.9% | |
| Mar 2026 | $11.45M USD | +11.2% | +84.9% | 12.0% | |
| Sep 2026 | $9.29M USD | +56.7% | -22.6% | 6.6% | |
| Peer median (excluding IMNM) | — | +17.5% | +14.1% | 13.5% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 49.23M | 20.32M | 98.68M | 143.35M | 653.48M |
| Short-term Investments | 0 | 0 | 39.46M | 73.95M | 0 |
| Net Receivables | 4.31M | 847K | 289K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 4.99M | 4.04M | 7.3M |
| Total Current Assets | 56.64M | 22.65M | 144.7M | 221.34M | 660.78M |
| Property, Plant & Equipment (Net) | 855K | 965K | 3.64M | 14.39M | 17.61M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 100K | 0 | 100K | 0 | 210K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 332K | 432K | 100K | 4.51M | 4.59M |
| Total Non-current Assets | 1.29M | 1.4M | 3.84M | 18.9M | 22.41M |
| Total Assets | 57.93M | 24.05M | 148.54M | 240.24M | 683.19M |
| Account Payables | 3.08M | 2.4M | 3.31M | 14.19M | 3.34M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 10.49M | 6.94M | 0 |
| Other Current Liabilities | 2.02M | 1.96M | 4.98M | 8M | 15.15M |
| Total Current Liabilities | 9.73M | 7.33M | 21.83M | 54.31M | 44.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 3.86M |
| Deferred Tax Liabilities | 0 | 0 | (5.49M) | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 5.49M | 0 | 0 |
| Other Non-current Liabilities | 12K | 0 | 5.49M | 0 | 0 |
| Total Non-current Liabilities | 12K | 62K | 6.83M | 4.77M | 3.86M |
| Total Liabilities | 9.74M | 7.39M | 28.66M | 59.08M | 48.85M |
| Common Stock | 1K | 1K | 4K | 6K | 11K |
| Retained Earnings | (79.11M) | (116M) | (222.81M) | (515.77M) | (728.16M) |
| Accumulated OCI | (57.93M) | 0 | 22K | 57K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 48.19M | 16.65M | 119.88M | 181.17M | 634.34M |
| Total Debt | 317K | 291K | 1.65M | 4.83M | 3.86M |
| Net Debt | (48.91M) | (20.03M) | (97.03M) | (138.52M) | (649.63M) |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.